Genus And 2 More Undervalued Small Caps With Insider Action

In This Article:

In the current global market landscape, small-cap stocks have faced varied challenges and opportunities. The S&P 600 Index, representing small-cap companies, has seen fluctuations amid geopolitical tensions in the Middle East and robust job gains in the U.S., creating a complex environment for investors. In such conditions, identifying promising stocks often involves looking at companies with strong fundamentals and insider activity that could indicate confidence in their potential.

Top 10 Undervalued Small Caps With Insider Buying

Name

PE

PS

Discount to Fair Value

Value Rating

Bytes Technology Group

26.0x

5.9x

6.38%

★★★★★☆

Trican Well Service

7.2x

0.9x

18.25%

★★★★★☆

PSC

8.0x

0.4x

40.32%

★★★★☆☆

Citizens & Northern

12.7x

2.9x

44.08%

★★★★☆☆

Studsvik

19.8x

1.2x

43.60%

★★★★☆☆

Franklin Financial Services

9.7x

1.9x

39.40%

★★★★☆☆

Optima Health

NA

1.2x

41.35%

★★★★☆☆

Community West Bancshares

18.7x

2.9x

42.25%

★★★☆☆☆

Sabre

NA

0.4x

-57.60%

★★★☆☆☆

Industrial Logistics Properties Trust

NA

0.7x

-218.04%

★★★☆☆☆

Click here to see the full list of 189 stocks from our Undervalued Small Caps With Insider Buying screener.

Let's explore several standout options from the results in the screener.

Genus

Simply Wall St Value Rating: ★★★★☆☆

Overview: Genus is a company specializing in animal genetics, providing advanced breeding services and products primarily through its Genus ABS and Genus PIC segments, with a market capitalization of £1.88 billion.

Operations: Genus derives its revenue primarily from Genus ABS and Genus PIC, contributing £314.90 million and £352.50 million respectively. The company's gross profit margin has shown variability, reaching as high as 68.02% in March 2024 and a notable peak of 100% in June 2024 due to unreported COGS figures for that period. Operating expenses have fluctuated significantly, with a recent high of £614.90 million reported in June 2024, impacting net income margins which have varied over time but were recorded at approximately 1.18% during the same period.

PE: 178.9x

Genus, a smaller company in its sector, recently reported annual sales of £668.8 million, down from £689.7 million the previous year, with net income falling to £7.9 million from £33.3 million. Despite these challenges and lower profit margins at 1.2%, insider confidence is evident through share purchases over the past year. The company maintains a consistent dividend of 21.7 pence per share and forecasts earnings growth of 37% annually, suggesting potential for future value realization despite relying on higher-risk external borrowing sources for funding.